Labcorp Holdings Inc. completed the sale of its Early Development medical device testing business to NAMSA on January 8 2026. The transaction, which transferred Labcorp’s U.S. portfolio of biocompatibility, microbiological, analytical and pre‑clinical research services, was announced on the same day and the deal value was not disclosed publicly.
The divestiture reflects Labcorp’s strategy to concentrate resources on its Diagnostics Laboratories and Biopharma Laboratory Services segments, which together generated more than $13 billion in annual revenue. Labcorp’s Early Development unit had posted only a 3.3 % revenue increase in Q3 2025, a modest growth that prompted the company to “take action” in the unit, according to its earnings guidance. By shedding this non‑core arm, Labcorp aims to streamline operations, reduce overhead and accelerate investment in high‑margin specialty testing and digital pathology initiatives.
NAMSA, a global leader in medical device testing and regulatory consulting, will assume responsibility for all existing Labcorp clients in the early‑development space. The acquisition expands NAMSA’s U.S. portfolio and marks its tenth U.S. acquisition since becoming an ARCHIMED company in 2020. NAMSA serves more than 3,000 MedTech companies worldwide, positioning the firm to deepen its footprint in biocompatibility, microbiology, sterility and pre‑clinical testing.
While the Early Development business contributed a small fraction of Labcorp’s $13 billion-plus revenue base, its divestiture is expected to be offset by growth in core segments. Labcorp’s Q4 2024 revenue was $3.33 billion, and the company projected full‑year 2025 revenue of $13.88 billion to $14.05 billion, underscoring the focus on high‑growth areas. The sale allows Labcorp to reallocate capital toward oncology, neurology, women’s health and other specialty testing verticals that offer higher margins.
Brian Caveney, EVP and President of Early Development Research Laboratories at Labcorp, said the sale “allows Labcorp to focus on core areas of pre‑clinical drug development and chemical testing.” NAMSA CEO Brian Smith added, “This acquisition is a perfect fit for NAMSA – we serve 3,000+ MedTech companies globally in these specific areas of testing and pre‑clinical research.”
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.